Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control.

Hiroyuki ItoRie ArakiSuzuko MatsumotoTakuma IzutsuEiji KusanoJiro KondoHideyuki InoueShinichi AntokuTomoko YamasakiToshiko MoriMichiko Togane

Published in: Diabetology international (2021)

Dulaglutide is considered effective in patients with type 2 diabetes and inadequate glycemic control, regardless of whether their pretreatment includes daily GLP-1 RA treatment.

Keyphrases

glycemic control
type diabetes
blood glucose
weight loss
insulin resistance
rheumatoid arthritis
disease activity
systemic lupus erythematosus
ankylosing spondylitis
metabolic syndrome
systemic sclerosis
smoking cessation